Clinical Trial Update: The Safety and Dosimetry Study of 177Lu-LNC1003 Injection [Phase 1]

View source ↗

Summary

Phase 1 safety and dosimetry study of the radiopharmaceutical 177Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• 177Lu-LNC1003 Injection (Lu-177-LNC1003)

Snippet

Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. | Conditions: Metastatic Castration-resistant Prostate Cancer, mCRPC | Phase 1 | Status: UNKNOWN